Knight Therapeutics, Inc. (GUD.TO)
12.06
+0.01
(+0.08%)
CAD |
TSX |
Nov 13, 16:00
Knight Therapeutics Enterprise Value : 1.082B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.082B |
| November 12, 2026 | 1.081B |
| November 11, 2026 | 1.079B |
| November 10, 2026 | 1.074B |
| November 09, 2026 | 1.037B |
| November 06, 2026 | 1.019B |
| November 05, 2026 | 1.033B |
| November 04, 2026 | 1.007B |
| November 03, 2026 | 1.003B |
| November 02, 2026 | 1.009B |
| October 30, 2026 | 1.004B |
| October 29, 2026 | 1.017B |
| October 28, 2026 | 1.008B |
| October 27, 2026 | 1.005B |
| October 26, 2026 | 1.040B |
| October 23, 2026 | 1.038B |
| October 22, 2026 | 1.046B |
| October 21, 2026 | 1.046B |
| October 20, 2026 | 1.022B |
| October 19, 2026 | 1.008B |
| October 16, 2026 | 981.58M |
| October 15, 2026 | 957.99M |
| October 14, 2026 | 939.32M |
| October 13, 2026 | 946.20M |
| October 09, 2026 | 960.94M |
| Date | Value |
|---|---|
| October 08, 2026 | 951.11M |
| October 07, 2026 | 949.15M |
| October 06, 2026 | 932.44M |
| October 05, 2026 | 914.75M |
| October 02, 2026 | 910.82M |
| October 01, 2026 | 942.27M |
| September 30, 2026 | 937.35M |
| September 29, 2026 | 941.29M |
| September 28, 2026 | 933.43M |
| September 25, 2026 | 935.40M |
| September 24, 2026 | 916.73M |
| September 23, 2026 | 915.75M |
| September 22, 2026 | 935.40M |
| September 21, 2026 | 924.59M |
| September 18, 2026 | 931.47M |
| September 17, 2026 | 929.50M |
| September 16, 2026 | 907.89M |
| September 15, 2026 | 902.98M |
| September 14, 2026 | 908.88M |
| September 11, 2026 | 892.18M |
| September 10, 2026 | 880.39M |
| September 09, 2026 | 897.09M |
| September 08, 2026 | 897.09M |
| September 04, 2026 | 907.89M |
| September 03, 2026 | 910.84M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 154.12M |
| Bausch Health Cos., Inc. | 31.74B |
| Cipher Pharmaceuticals, Inc. | 336.68M |
| BioSyent, Inc. | 195.94M |
| Revive Therapeutics Ltd. | 6.520M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.68M |
| Revenue (Quarterly) | 137.69M |
| Total Expenses (Quarterly) | 140.37M |
| EPS Diluted (Quarterly) | -0.0273 |
| Gross Profit Margin (Quarterly) | 38.94% |
| Profit Margin (Quarterly) | -1.95% |
| Earnings Yield | 1.33% |
| Operating Earnings Yield | 2.63% |
| Normalized Earnings Yield | 2.090 |